Published:
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal 2009
KAILUA KONA, Hawaii - (BUSINESS WIRE) - Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in
microalgae-based, high-value nutrition and health products, today
announced financial results for the fourth quarter and fiscal 2009,
ended March 31, 2009.
Fiscal 2009
Revenues for fiscal 2009 increased 23% to $13,950,000, compared to
revenues of $11,364,000 for fiscal 2008. Gross profit was $5,512,000,
with gross profit margin of 40%, compared to a gross profit of
$3,071,000 and gross profit margin of 27% reported for fiscal 2008. Net
income was $1,142,000, or $0.22 per diluted share, compared to a net
loss of $1,139,000, or ($0.22) per diluted share for fiscal 2008.
Cash and cash equivalents were $977,000 at March 31, 2009 compared to
the March 31, 2008 balance of $1,090,000. Working capital increased to
$3,892,000 at March 31, 2009 compared to $3,092,000 at March 31, 2008.
"In fiscal 2009, we focused on stabilizing Cyanotech by driving sound
business fundamentals throughout the organization, thereby creating a
strong foundation for the future," said Andrew H. Jacobson, President
and Chief Executive Officer.
Mr. Jacobson noted these highlights and results of the company's fiscal
2009 plan:
|
|
|
1)
|
|
Quality - Cyanotech established Hawaiian Spirulina
Pacifica as the global nutritional leader. Third party tests
confirmed superior nutritional content across all leading brands.
In addition, Cyanotech significantly improved the potency of its
Astaxanthin biomass.
|
|
|
|
|
|
|
|
|
|
2)
|
|
Cost Containment - Consolidating vendors, reducing costs
and implementing controls throughout the supply chain delivered a
13-point margin improvement.
|
|
|
|
|
|
|
|
|
|
3)
|
|
Increased Productivity - New cultivation strategies,
combined with adherence to stringent production metrics, increased
Spirulina productivity by 52% and Astaxanthin productivity by 18%.
|
|
|
|
|
|
|
|
|
|
4)
|
|
Sales Growth - Sales increased 23% through improved service
levels, a strategic price increase across all classes of trade and
marketing of the Hawaii difference.
|
|
|
|
|
|
|
|
|
|
5)
|
|
Net Income - Cyanotech delivered $1.142 million in net
income, which represents a $2.281 million turnaround.
|
|
|
|
|
|
|
"We are excited about fiscal 2010 and will continue to focus on sound
business fundamentals. In addition, we will introduce a number of
innovative products that will feature our Hawaiian Spirulina Pacifica
and BioAstin Natural Astaxanthin," Mr. Jacobson concluded.
Fourth Quarter Fiscal 2009
Revenues for the fourth quarter of fiscal 2009 were $3,422,000, compared
to revenues of $3,414,000 for the fourth quarter of fiscal 2008. Gross
profit for the fourth quarter was $1,264,000, with gross profit margin
of 37%, compared to a gross profit of $1,204,000 and gross profit margin
of 35% reported for the fourth quarter of fiscal 2008. Net income for
the fourth quarter was $194,000, or $0.04 per diluted share, compared to
net income of $181,000, or $0.03 per diluted share for the fourth
quarter of fiscal 2008. Lower temperatures and reduced sunlight during
the winter months contributed to seasonally reduced productivity in the
fourth quarter.
About Cyanotech - Cyanotech Corporation, a world leader in
microalgae technology, produces BioAstin Natural Astaxanthin and
Hawaiian Spirulina Pacifica-all natural, functional nutrients
that leverage our experience and reputation for quality, building
nutritional brands which promote health and well-being. Cyanotech's
Spirulina products offer complete nutrition, and augment energy and
immune response. They are FDA reviewed and accepted as Generally
Recognized as Safe (GRAS) for use in food products. BioAstin's superior
antioxidant activity and ability to support and maintain a natural
anti-inflammatory response enhance skin, muscle and joint health. All
Cyanotech products are produced from microalgae grown at its 90-acre
facility in Kona, Hawaii using patented and proprietary technology.
Cyanotech distributes to nutritional supplement, nutraceutical and
cosmeceutical manufacturers and marketers in more than 40 countries
worldwide. Cyanotech was the first microalgae company in the
world to obtain quality management standards ISO 9001:2000 certification
and is GMP-certified by the Natural Products AssociationTM.
Visit www.cyanotech.com
for more information.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995
Except for statements of historical fact, the statements in this press
release are forward-looking. Such statements are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from the statements made. These factors include, but are not
limited to, general economic conditions, forecasts of sales in future
periods, changes in sales levels to our largest customers, weather
patterns, production problems caused by contamination, risks associated
with the acceptance of new products, competition, foreign exchange
fluctuations, government regulation, and other factors more fully
detailed in the Company's recent Form 10-Q and annual Form 10-K filings
with the Securities and Exchange Commission.
(Financial Tables Follow: The following tables do not contain
footnotes or other information contained in the Company's Form 10-K for
the periods ended March 31, 2009. As such the following Financial Tables
are provided only as a guide and other factors are more fully detailed
in the Company's annual Form 10-K filing with the Securities and
Exchange Commission.)
|
|
|
|
|
|
|
|
|
|
|
CYANOTECH CORPORATION
|
|
CONSOLIDATED CONDENSED BALANCE SHEETS
|
|
March 31, 2009 and 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
2008
|
|
|
|
(in thousands, except
share data)
|
|
ASSETS
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
977
|
|
|
$
|
1,090
|
|
|
Accounts receivable, net of allowance for doubtful accounts of $14
in 2009 and $23 in 2008
|
|
|
1,785
|
|
|
|
1,934
|
|
|
Inventories
|
|
|
3,124
|
|
|
|
1,601
|
|
|
Prepaid expenses and other current assets
|
|
|
110
|
|
|
|
263
|
|
|
Total current assets
|
|
|
5,996
|
|
|
|
4,888
|
|
|
Equipment and leasehold improvements, net
|
|
|
4,316
|
|
|
|
4,269
|
|
|
Other assets
|
|
|
475
|
|
|
|
623
|
|
|
Total assets
|
|
$
|
10,787
|
|
|
$
|
9,780
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Current maturities of long-term debt
|
|
$
|
620
|
|
|
$
|
567
|
|
|
Accounts payable
|
|
|
1,040
|
|
|
|
805
|
|
|
Accrued expenses
|
|
|
444
|
|
|
|
320
|
|
|
Customer deposit
|
|
|
-
|
|
|
|
104
|
|
|
Total current liabilities
|
|
|
2,104
|
|
|
|
1,796
|
|
|
Long-term debt, excluding current maturities
|
|
|
909
|
|
|
|
1,505
|
|
|
Customer deposit
|
|
|
-
|
|
|
|
100
|
|
|
Total liabilities
|
|
|
3,013
|
|
|
|
3,401
|
|
|
Stockholders' equity:
|
|
|
|
|
|
Common stock of $.02 par value, authorized 7,500,000 shares; issued
and outstanding 5,245,770 shares at 2009 and 5,242,270 shares at 2008
|
|
|
105
|
|
|
|
105
|
|
|
Additional paid-in capital
|
|
|
27,590
|
|
|
|
27,337
|
|
|
Accumulated other comprehensive loss
|
|
|
-
|
|
|
|
(4
|
)
|
|
Accumulated deficit
|
|
|
(19,921
|
)
|
|
|
(21,059
|
)
|
|
Total stockholders' equity
|
|
|
7,774
|
|
|
|
6,379
|
|
|
Total liabilities and stockholders' equity
|
|
$
|
10,787
|
|
|
$
|
9,780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CYANOTECH CORPORATION
|
|
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
|
|
For the fiscal years ended March 31, 2009, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
2008
|
|
2007
|
|
|
|
(in thousands, except
per share data)
|
|
Net sales
|
|
$
|
13,950
|
|
|
$
|
11,364
|
|
|
$
|
9,683
|
|
|
Cost of sales
|
|
|
8,438
|
|
|
|
8,293
|
|
|
|
8,552
|
|
|
Gross profit
|
|
|
5,512
|
|
|
|
3,071
|
|
|
|
1,131
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
Research and development
|
|
|
206
|
|
|
|
143
|
|
|
|
203
|
|
|
Sales and marketing
|
|
|
1,125
|
|
|
|
1,355
|
|
|
|
1,297
|
|
|
General and administrative
|
|
|
2,873
|
|
|
|
2,478
|
|
|
|
2,448
|
|
|
Impairment loss on equipment and leasehold improvements
|
|
|
-
|
|
|
|
-
|
|
|
|
4,487
|
|
|
Total operating expense
|
|
|
4,204
|
|
|
|
3,976
|
|
|
|
8,435
|
|
|
Income (loss) from operations
|
|
|
1,308
|
|
|
|
(905
|
)
|
|
|
(7,304
|
)
|
|
Other income (expense):
|
|
|
|
|
|
|
|
Interest income
|
|
|
8
|
|
|
|
24
|
|
|
|
59
|
|
|
Interest expense
|
|
|
(162
|
)
|
|
|
(164
|
)
|
|
|
(186
|
)
|
|
Other income (expense), net
|
|
|
10
|
|
|
|
(65
|
)
|
|
|
(3
|
)
|
|
Total other expense, net
|
|
|
(144
|
)
|
|
|
(205
|
)
|
|
|
(130
|
)
|
|
Income (loss) before income tax expense (benefit)
|
|
|
1,164
|
|
|
|
(1,110
|
)
|
|
|
(7,434
|
)
|
|
Income tax expense (benefit)
|
|
|
22
|
|
|
|
29
|
|
|
|
(9
|
)
|
|
Net income (loss)
|
|
$
|
1,142
|
|
|
$
|
(1,139
|
)
|
|
$
|
(7,425
|
)
|
|
Net income (loss) per share:
|
|
|
|
|
|
|
|
Basic
|
|
$
|
.22
|
|
|
$
|
(.22
|
)
|
|
$
|
(1.42
|
)
|
|
Diluted
|
|
$
|
.22
|
|
|
$
|
(.22
|
)
|
|
$
|
(1.42
|
)
|
|
Shares used in calculation of net income (loss) per share:
|
|
|
|
|
|
|
|
Basic
|
|
|
5,244
|
|
|
|
5,242
|
|
|
|
5,234
|
|
|
Diluted
|
|
|
5,248
|
|
|
|
5,242
|
|
|
|
5,234
|
|
Cyanotech Corporation Bruce Russell, 310-559-4955 x101 brussell@cyanotech.com
Copyright © 2009, Business Wire, Inc., All rights reserved. Copyright © 2009, NewsBlaze, Daily News
Tags: Business wire, Healthcare, hawaii, Health, Biotechnology _ _
|